Vasohibin attenuates bleomycin induced pulmonary fibrosis via inhibition of angiogenesis in mice

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Pathology (Sydney)

• Publication date

  2010-07-15

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.3109/00313025.2010.493864PMID 20632823
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast.

  2009cited by this paper
• Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms

  2009cited by this paper
• Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients.

  2008cited by this paper
• Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review.

  2008cited by this paper
• Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis.

  2008cited by this paper
• Expression of vasohibin, an antiangiogenic factor, in human choroidal neovascular membranes.

  2008cited by this paper
• Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit.

  2008cited by this paper
• Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2.

  2008cited by this paper
• 2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model.

  2008cited by this paper
• New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis: A Potential Role for Stem Cells in the Lung Parenchyma and Implications for Therapy

  2007cited by this paper
• Angiogenesis in chronic lung disease.

  2007cited by this paper
• Vasohibin prevents arterial neointimal formation through angiogenesis inhibition.

  2006cited by this paper
• Chemokine-mediated angiogenesis: an essential link in the evolution of airway fibrosis?

  2005cited by this paper
• Anti-Vascular Endothelial Growth Factor Gene Therapy Attenuates Lung Injury and Fibrosis in Mice1

  2005cited by this paper
• [Pneumology. Treatment of idiopathic pulmonary fibrosis: hopes and disappointment].

  2005cited by this paper
• Pneumologie : Traitement de la fibrose pulmonaire idiopathique : un espoir après une désillusion

  2005cited by this paper
• Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in three-dimensional collagen gels.

  2005cited by this paper
• Antioxidant therapy for idiopathic pulmonary fibrosis.

  2005cited by this paper
• Proliferation of Pulmonary Interstitial Fibroblasts Is Mediated by Transforming Growth Factor-β1-induced Release of Extracellular Fibroblast Growth Factor-2 and Phosphorylation of p38 MAPK and JNK*

  2005cited by this paper
• Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis.

  2004cited by this paper
• Vasohibin: the feedback on a new inhibitor of angiogenesis.

  2004cited by this paper
• VEGF and the quest for tumour angiogenesis factors

  2002cited by this paper
• Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF

  2002cited by this paper
• ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis.

  2001cited by this paper
• Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF.

  2001cited by this paper
• The discovery of angiogenic factors: a historical review.

  2000cited by this paper
• Fibrosis and angiogenesis.

  2000cited by this paper
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

  2000cited by this paper
• Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement

  2000cited by this paper
• IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis.

  1999cited by this paper
• Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis.

  1999cited by this paper
• Vascular endothelial growth factor (VEGF)‐C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity

  1998cited by this paper
• The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis.

  1997cited by this paper
• Identification and partial characterization of angiogenesis bioactivity in the lower respiratory tract after acute lung injury.

  1991cited by this paper
• Mechanisms of alveolar fibrosis after acute lung injury.

  1990cited by this paper
• Feedback regulators in normal and tumour tissues

  1988cited by this paper
• Precapillary Systemic-pulmonary Anastomoses

  1963cited by this paper
• The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid.

  1961influential reference

• A Multispecies, Modality-Agnostic Scalable In Vivo Mosaic Screening Platform for Therapeutic Target Discovery

  2026cites this paper
• Progressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium

  2025cites this paper
• Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis

  2025cites this paper
• Vasohibins in Health and Disease: From Angiogenesis to Tumorigenesis, Multiorgan Dysfunction, and Brain–Heart Remodeling

  2025cites this paper
• Pulmonary fibrosis: risk factors, pathogenesis and in vivo/in vitro experimental modeling

  2023cites this paper
• Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions

  2021cites this paper
• In search of the needle in a haystack: Finding a suitable serum biomarker for monitoring disease activity of systemic sclerosis

  2021cites this paper
• Vascular Endothelial Growth Factor and Inflammatory Airway Diseases: An Update

  2021cites this paper
• Gene fusion of IL7 involved in the regulation of idiopathic pulmonary fibrosis

  2021cites this paper
• VEGF and FGF-2: Promising targets for the treatment of respiratory disorders.

  2019cites this paper
• Targeting of Discoidin Domain Receptor 2 (DDR2) Prevents Myofibroblast Activation and Neovessel Formation During Pulmonary Fibrosis.

  2016cites this paper
• Genome-wide analysis of DNA methylation and gene expression defines molecular characteristics of Crohn’s disease-associated fibrosis

  2016influential citation
• A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin‐induced pulmonary fibrosis

  2016cites this paper
• Fibrocytes and Pulmonary Vascular Remodeling: The Good, the Bad, and the Progenitors

  2015cites this paper
• Inhibition of IGF-1-Mediated Cellular Migration and Invasion by Migracin A in Ovarian Clear Cell Carcinoma Cells

  2015cites this paper
• Kinetics of the angiogenic response in lung endothelium following acute inflammatory injury with bleomycin

  2014cites this paper
• Emerging therapeutic interventions for idiopathic pulmonary fibrosis

  2014cites this paper
• Vasohibin‐1 deficiency enhances renal fibrosis and inflammation after unilateral ureteral obstruction

  2014cites this paper
• Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats

  2013influential citation
• The vasohibin family: a novel family for angiogenesis regulation.

  2013cites this paper
• Apoptosis and angiogenesis: an evolving mechanism for fibrosis

  2013cites this paper